Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
about
The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot studyTreatment of metabolic syndromeBeneficial effects of pioglitazone and metformin in murine model of polycystic ovaries via improvement of chemerin gene up-regulation.Effectiveness of long-term (twelve months) nonsurgical weight loss interventions for obese women with polycystic ovary syndrome: a systematic reviewState of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS).Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS).Recent advances in the treatment of polycystic ovary syndrome.Insulin-sensitisers in the treatment of polycystic ovary syndrome.The effects of old, new and emerging medicines on metabolic aberrations in PCOS.Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndromeDiet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management.Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications.Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeysThe effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome.Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome.Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT.Targeting insulin sensitivity in the treatment of polycystic ovary syndrome.Thiazolinedione treatment in PCOS--an update.Polycystic ovary syndrome: an overview.Economic benefits of pioglitazone for treating patients with Type 2 diabetes.Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
P2860
Q25257236-30C23C97-4EA5-40CD-A8EC-28B68709BAD7Q28168652-D908619A-8F62-49F9-97E9-1E107623C22AQ33559740-53D29855-67F1-4C03-AD65-4B29276C996EQ34345731-603E3A69-8D1F-446A-B04E-703783F3726FQ35233754-C6EC628B-3234-47CC-B769-E78B5C5B5B2AQ35606054-A447375B-B574-4CBC-8187-B6AC542FA11CQ35906966-F662CA4A-0D3B-4C10-B4A9-C813FCFAC38BQ36301573-3E7BE3FD-2B34-47AF-8279-7DD19E1489CEQ36328060-5067DFB9-48DF-437A-9413-B5B09CF6C398Q36328993-9E47FC77-977A-4E5F-AE50-5669B534A499Q37022386-DEDAF1F4-3352-4512-ABB0-6831F9F7012BQ37039725-67E44EFE-2B3E-4912-AD15-4BECFE87757CQ37071255-95095BBC-56C4-4573-8CAE-B36F5D701059Q37250408-2E9E43EB-662E-4A0C-81DB-20718DD024CAQ37402281-AAA87C44-A60D-456F-AEE1-184220BC9B53Q37409121-0AAF4FD4-69E1-4B50-B7BC-B20D84BA239DQ37547069-26413D9B-F3CC-4A36-A668-59F0CD8FC0F1Q37570577-95F5F17F-0805-484D-A128-FBED6276C3C7Q37763184-54FF6620-145C-4669-8C10-E55BA91F95F5Q37886072-DBD07D33-6DA0-41DA-B28F-0B943CD09306Q43266404-3F6E52C8-5915-4120-864C-ED13C1130E21Q46545539-B4114A48-0C99-4736-AC0C-5DEA1A27ACCB
P2860
Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Pioglitazone and metformin in ...... mally responsive to metformin.
@en
Pioglitazone and metformin in ...... mally responsive to metformin.
@nl
type
label
Pioglitazone and metformin in ...... mally responsive to metformin.
@en
Pioglitazone and metformin in ...... mally responsive to metformin.
@nl
prefLabel
Pioglitazone and metformin in ...... mally responsive to metformin.
@en
Pioglitazone and metformin in ...... mally responsive to metformin.
@nl
P2093
P921
P356
P1433
P1476
Pioglitazone and metformin in ...... mally responsive to metformin.
@en
P2093
Andrew Moreira
Charles J Glueck
Luann Sieve
Naila Goldenberg
P304
P356
10.1093/HUMREP/DEG343
P407
P577
2003-08-01T00:00:00Z